```
     FILE 'REGISTRY' ENTERED AT 12:37:15 ON 28 MAY 2009
                  EXP TRIACETYLCYTIDINE/CN

     FILE 'STNGUIDE' ENTERED AT 12:37:29 ON 28 MAY 2009

     FILE 'HCAPLUS' ENTERED AT 12:42:38 ON 28 MAY 2009
L1            52 S TRIACETYLCYTIDINE OR TRIACETYLURIDINE OR ETHOXYCARBONYLURIDIN

     FILE 'STNGUIDE' ENTERED AT 12:43:00 ON 28 MAY 2009

     FILE 'HCAPLUS' ENTERED AT 12:43:44 ON 28 MAY 2009
L2         24237 S FLUOROURACIL OR FLUOROOROTATE OF TEGAFUR OR FLUOROURIDINE OR
L3          9003 S (ARABINOSYL(2A)CYTOSINE) OR CYCLOCYTIDINE OR (AZA(2A)CYTIDINE
L4         66014 S AZARIBINE OR THYMIDINE OR DEAZAURIDINE OR DIDEOXYCYTIDINE OR
L5            15 S L1 AND (L2 OR L3 OR L4)
L6            34 S L1 AND (PY<1993 OR AY<1993 OR PRY<1993)
L7             9 S L5 AND (PY<1993 OR AY<1993 OR PRY<1993)


     FILE 'HCAPLUS' ENTERED AT 12:48:14 ON 28 MAY 2009
L8            25 S L6 NOT L7


     FILE 'REGISTRY' ENTERED AT 12:50:41 ON 28 MAY 2009
                  EXP 2,3,5 TRIACETYLURIDINE/CN
                  EXP 2,3,5-TRIACETYLURIDINE/CN
                  EXP ETHOXYCARBONYLURIDINE/CN
L9                STRUCTURE UPLOADED
L10              50 S L9
L11            1403 S L9 SSS FULL
                  EXP URIDINE/CN
L12               1 S E3
L13               1 S CYTIDINE/CN
L14            1401 S L11 NOT (L12 OR L13)

     FILE 'HCAPLUS' ENTERED AT 13:18:56 ON 28 MAY 2009
L15             100 S L14/THU
L16            1204 S L14 AND (PY<1993 OR AY<1993 OR PRY<1993)
L17              13 S L15 AND (PY<1993 OR AY<1993 OR PRY<1993)
L18           38607 S URIDINE OR CYTIDINE
L19            8772 S L18 AND (L2 OR L3 OR L4)
L20            6282 S L19 AND (PY<1993 OR AY<1993 OR PRY<1993)
L21          397890 S TOXICITY OR (SIDE EFFECT)
L22             269 S L20 AND L21

     FILE 'STNGUIDE' ENTERED AT 13:46:29 ON 28 MAY 2009

     FILE 'REGISTRY' ENTERED AT 13:46:36 ON 28 MAY 2009
                  EXP CYTIDINE/CN
L23               0 S (L12 OR L13) AND (L2-L4)
L24               1 S L12

     FILE 'HCAPLUS' ENTERED AT 13:48:10 ON 28 MAY 2009
L25             411 S (L12/THU OR L13/THU)
L26             164 S L25 AND (L2-L4)
L27              22 S L26 AND (PY<1993 OR AY<1993 OR PRY<1993)
```

```
Welcome to STN International!  Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:
  * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 13:17:02 ON 28 MAY 2009
FILE 'REGISTRY' ENTERED AT 13:17:02 ON 28 MAY 2009
COPYRIGHT (C) 2009 American Chemical Society (ACS)f

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.96      77.53

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00     -13.94

=>
Uploading
FUPLOAD IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

C:\Program Files\STNEXP\Queries\08460186acylated2.str

L9      STRUCTURE UPLOADED

=> s l9
SAMPLE SEARCH INITIATED 13:17:26 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     2255 TO ITERATE

 88.7% PROCESSED     2000 ITERATIONS                              50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        42252 TO    47948
PROJECTED ANSWERS:             732 TO     1658

L10          50 SEA SSS SAM L9

=> d l10 scan

L10  50 ANSWERS   REGISTRY  COPYRIGHT 2009 ACS on STN
IN   Cytidine, N-(1-oxodocosahexaenyl)- (9CI)
MF   C31 H43 N3 O6
CI   IDS

     CM   1

Absolute stereochemistry.
```



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):4

L10 50 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Adenosine, N-[2-[(1,2-dihydro-2-oxo-1-β-D-ribofuranosyl-4-pyrimidinyl)amino]ethyl]- (9CI)
MF C21 H28 N8 O9

Absolute stereochemistry.





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 50 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Cytidine, N-[(2,2,2-trichloro-1,1-dimethylethoxy)carbonyl]-, 2',3',5'-tris(2,2,2-trichloro-1,1-dimethylethyl carbonate) (9CI)
MF C29 H33 Cl12 N3 O13

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 50 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Uridine, 4-(dimethylhydrazone) (9CI)
MF C11 H18 N4 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 50 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Uridine, 2',3',5'-tris(4-methoxybenzoate) (9CI)
MF C33 H30 N2 O12

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l9 sss full
FULL SEARCH INITIATED 13:18:07 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 45024 TO ITERATE

100.0% PROCESSED 45024 ITERATIONS 1403 ANSWERS
SEARCH TIME: 00.00.01

L11 1403 SEA SSS FUL L9

=> exp uridine/cn
E1 1 URIDIN-5'-O-YL, 2'-DEOXY-/CN
E2 1 URIDINAL/CN
E3 1 --> URIDINE/CN
E4 1 URIDINE (CYTIDYLYL-(3'.FWDARW.5')-CYTIDYLYL-(3'.FWDARW.5')-C

```
                    YTIDYLYL-(3'.FWDARW.5')-GUANYLYL-(3'.FWDARW.5')-)/CN
E5          1       URIDINE (CYTIDYLYL-(3'.FWDARW.5')-URIDYLYL-(3'.FWDARW.5')-CY
                    TIDYLYL-(3'.FWDARW.5')-GUANYLYL-(3'.FWDARW.5')-URIDYLYL-(3'.
                    FWDARW.5')-GUANYLYL-(3'.FWDARW.5')-)/CN
E6          1       URIDINE (URIDYLYL-(2'.FWDARW.5')-URIDYLYL-(2'.FWDARW.5')-URI
                    DYLYL-(2'.FWDARW.5')-URIDYLYL-(2'.FWDARW.5')-URIDYLYL-(2'.FW
                    DARW.5')-URIDYLYL-(2'.FWDARW.5')-URIDYLYL-(2'.FWDARW.5')-)/C
                    N
E7          1       URIDINE 2',3'-ACETONIDE/CN
E8          1       URIDINE 2',3'-CYCLIC MONOPHOSPHATE/CN
E9          1       URIDINE 2',3'-CYCLIC PHOSPHOROTHIOATE/CN
E10         1       URIDINE 2',3'-CYCLOPHOSPHATE/CN
E11         1       URIDINE 2',3'-DIACETATE 5'-PHOSPHATE/CN
E12         1       URIDINE 2',3'-DIACETATE 5'-TRIPHOSPHATE/CN

=> s e3
L12         1 URIDINE/CN

=> s cytidine/cn
L13         1 CYTIDINE/CN

=> d l13 scan

L13  1 ANSWERS   REGISTRY  COPYRIGHT 2009 ACS on STN
IN   Cytidine
MF   C9 H13 N3 O5
CI   COM

Absolute stereochemistry.
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**


ALL ANSWERS HAVE BEEN SCANNED


=> d l12 scan

L12  1 ANSWERS   REGISTRY  COPYRIGHT 2009 ACS on STN
IN   Uridine
MF   C9 H12 N2 O6
CI   COM

Absolute stereochemistry.  Rotation (+).
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l11 nor (l12 or l13)
MISSING OPERATOR

=> s l11 not (l12 or l13)
L14 1401 L11 NOT (L12 OR L13)

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	198.50	275.07

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-13.94

FILE 'HCAPLUS' ENTERED AT 13:18:56 ON 28 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 28 May 2009 VOL 150 ISS 22
FILE LAST UPDATED: 27 May 2009 (20090527/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2009

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l14/thu
          1960 L14
       1128974 THU/RL
L15         100 L14/THU
                (L14 (L) THU/RL)

=> s l14 and (PY<1993 or AY<1993 or PRY<1993)
          1960 L14
      14940497 PY<1993
       2629968 AY<1993
       2070996 PRY<1993
L16       1204 L14 AND (PY<1993 OR AY<1993 OR PRY<1993)

=> s l15 and (PY<1993 or AY<1993 or PRY<1993)
      14940497 PY<1993
       2629968 AY<1993
       2070996 PRY<1993
L17         13 L15 AND (PY<1993 OR AY<1993 OR PRY<1993)

=> d l17 1-13 ti abs bib

L17  ANSWER 1 OF 13  HCAPLUS  COPYRIGHT 2009 ACS on STN
TI   Treatment of chemotherapeutic agent and antiviral agent toxicity with
     acylated pyrimidine nucleosides
AB   Compds., compns., and methods are disclosed for treatment and prevention
     of toxicity due to chemotherapeutic agents and antiviral agents.
     Disclosed are acylated derivs. of nonmethylated pyrimidine nucleosides.
     These compds. are capable of attenuating damage to the hematopoietic
     system in animals receiving antiviral or antineoplastic chemotherapy.
AN   1999:670113  HCAPLUS <<LOGINID::20090528>>
DN   131:281604
TI   Treatment of chemotherapeutic agent and antiviral agent toxicity with
     acylated pyrimidine nucleosides
IN   Von Borstel, Reid; Bamat, Michael K.
PA   Pro-Neuron, Inc., USA
SO   U.S., 31 pp., Cont.-in-part U. S. Ser. 176,485.
     CODEN: USXXAM
DT   Patent
LA   English
FAN.CNT 13
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   US 5968914           A     19991019    US 1995-472210         19950607 <--
     EP 712629            A1    19960522    EP 1995-203050         19881027 <--
     EP 712629            B1    20030618
          R:  AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE
     JP 10001436          A     19980106    JP 1997-36734          19881027 <--
     JP 3474073           B2    20031208
     JP 2001192335        A     20010717    JP 2000-379524         19881027 <--
     CA 2111571           A1    19930121    CA 1992-2111571        19920625 <--
     CA 2111571           C     20050823
     CA 2504078           A1    19930121    CA 1992-2504078        19920625 <--
     CA 2504078           C     20070828
     ES 2160579           T3    20011116    ES 1992-914215         19920625 <--
     ZA 9204975           A     19930428    ZA 1992-4975           19920703 <--
     IN 175688            A1    19950812    IN 1992-CA473          19920706 <--
     US 5246708           A     19930921    US 1992-911379         19920713 <--
     US 5470838           A     19951128    US 1992-997657         19921230 <--
```

```
     US 5583117            A     19961210    US 1993-140475          19931025 <--
     US 6020320            A     20000201    US 1993-153163          19931117 <--
     US 5736531            A     19980407    US 1993-176485          19931230 <--
     IN 177670             A1    19970215    IN 1994-CA701           19940902 <--
     US 5770582            A     19980623    US 1995-419767          19950410 <--
     US 5691320            A     19971125    US 1995-465454          19950605 <--
     US 6054441            A     20000425    US 1995-463790          19950605 <--
     US 6060459            A     20000509    US 1995-465016          19950605 <--
     US 7307166            B1    20071211    US 1995-463771          19950605 <--
     US 6258795            B1    20010710    US 1995-466145          19950606 <--
     US 6316426            B1    20011113    US 1995-466144          19950606 <--
     US 6232298            B1    20010515    US 1995-479519          19950607 <--
     US 6274563            B1    20010814    US 1995-479349          19950607 <--
     US 6348451            B1    20020219    US 1995-478736          19950607 <--
     US 6919320            B1    20050719    US 1995-473331          19950607 <--
     CA 2223640            A1    19961219    CA 1996-2223640         19960606
     WO 9640165            A1    19961219    WO 1996-US10067         19960606
        W:  AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE,
            ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS,
            LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD,
            SE, SG
        RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,
            IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN
     AU 9661114            A     19961230    AU 1996-61114           19960606
     AU 724805             B2    20000928
     EP 831849             A1    19980401    EP 1996-918461          19960606
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI
     CN 1192149            A     19980902    CN 1996-195929          19960606
     JP 10511689           T     19981110    JP 1997-502184          19960606
     JP 2003201240         A     20030718    JP 2003-721             19960606
     EP 1491201            A1    20041229    EP 2004-23557           19960606
     EP 1491201            B1    20060322
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, AL
     AT 320813             T     20060415    AT 2004-23557           19960606
     ES 2257721            T3    20060801    ES 2004-23557           19960606
     HK 1072897            A1    20060512    HK 2005-105421          19981003
     US 20010025032        A1    20010927    US 1999-249790          19990216 <--
     US 6344447            B2    20020205
     AU 9952624            A     19991202    AU 1999-52624           19991001
     US 6743782            B1    20040601    US 2000-494242          20000131 <--
     AU 2002320811         A1    20030403    AU 2002-320811          20021223
     US 20040033981        A1    20040219    US 2003-601863          20030624 <--
     US 20040192635        A1    20040930    US 2004-824501          20040415 <--
     US 20040220134        A1    20041104    US 2004-855835          20040528 <--
     AU 2005232288         A1    20051201    AU 2005-232288          20051110
     JP 2006137772         A     20060601    JP 2005-380457          20051228 <--
     JP 2008019268         A     20080131    JP 2007-233452          20070907 <--
PRAI US 1987-115923        B2    19871028  <--
     US 1987-115929        B2    19871028  <--
     US 1989-438493        B2    19890627  <--
     US 1990-487984        B2    19900205  <--
     US 1991-724340        B2    19910705  <--
     US 1992-903107        B2    19920625  <--
     US 1993-61381         B2    19930514
     US 1993-176485        A2    19931230
     US 1988-186031        B2    19880425  <--
     EP 1988-910239        A3    19881027  <--
     JP 1988-509176        A3    19881027  <--
     JP 1994-303877        A3    19881027  <--
```

JP	2000-379524	A3	19881027	<--
US	1989-341925	B1	19890421	<--
US	1990-533933	B1	19900605	<--
US	1990-438493	B2	19900626	<--
US	1991-653882	B2	19910208	<--
US	1991-737913	B3	19910729	<--
CA	1992-2111571	A3	19920625	<--
IN	1992-CA473	A1	19920706	<--
US	1992-911379	A3	19920713	<--
US	1992-925931	B2	19920807	<--
US	1992-958598	B3	19921007	<--
US	1992-987730	B2	19921208	<--
US	1992-997657	A3	19921230	<--
US	1993-96407	B1	19930726	
US	1993-98884	B1	19930729	
US	1993-153163	A1	19931117	
US	1993-158799	B2	19931201	
US	1994-266897	B3	19940701	
US	1994-289214	A3	19940812	
US	1995-419767	A3	19950410	
US	1995-463740	A1	19950605	
US	1995-472210	A	19950607	
AU	1995-29150	A3	19950630	
EP	1996-918461	A3	19960606	
JP	1997-502184	A3	19960606	
WO	1996-US10067	W	19960606	
HK	1998-111095	A3	19981003	
AU	1999-52624	A3	19991001	
US	2000-494242	A3	20000131	
AU	2002-320811	A3	20021223	
JP	2005-380457	A3	20051228	

RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 13 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
AB The subject invention discloses compds., compns. and methods for treatment and prevention of toxicity due to chemotherapeutic agents and antiviral agents. Disclosed are acylated derivs. of non-methylated pyrimidine nucleosides. These compds. are capable of attenuating damage to the hematopoietic system in animals receiving antiviral or antineoplastic chemotherapy. Thus, biol activity of 5-fluorouracil is reported.
AN 1998:236253 HCAPLUS <<LOGINID::20090528>>
DN 128:266247
OREF 128:52559a,52562a
TI Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
IN Von Borstel, Reid W.; Bamat, Michael K.
PA Pro-Neuron, Inc., USA
SO U.S., 26 pp., Cont.-in-part of U.S. Ser. No. 61,381, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 13

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5736531	A	19980407	US 1993-176485	19931230 <--
EP 712629	A1	19960522	EP 1995-203050	19881027 <--
EP 712629	B1	20030618		

R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

	JP 10001436	A	19980106	JP 1997-36734	19881027	<--
	JP 3474073	B2	20031208			
	JP 2001192335	A	20010717	JP 2000-379524	19881027	<--
	CA 2111571	A1	19930121	CA 1992-2111571	19920625	<--
	CA 2111571	C	20050823			
	CA 2504078	A1	19930121	CA 1992-2504078	19920625	<--
	CA 2504078	C	20070828			
	ES 2160579	T3	20011116	ES 1992-914215	19920625	<--
	ZA 9204975	A	19930428	ZA 1992-4975	19920703	<--
	IN 175688	A1	19950812	IN 1992-CA473	19920706	<--
	US 5246708	A	19930921	US 1992-911379	19920713	<--
	US 5470838	A	19951128	US 1992-997657	19921230	<--
	US 5583117	A	19961210	US 1993-140475	19931025	<--
	US 6020320	A	20000201	US 1993-153163	19931117	<--
	IN 177670	A1	19970215	IN 1994-CA701	19940902	<--
	US 5770582	A	19980623	US 1995-419767	19950410	<--
	US 5691320	A	19971125	US 1995-465454	19950605	<--
	US 6054441	A	20000425	US 1995-463790	19950605	<--
	US 6060459	A	20000509	US 1995-465016	19950605	<--
	US 7307166	B1	20071211	US 1995-463771	19950605	<--
	US 6258795	B1	20010710	US 1995-466145	19950606	<--
	US 6316426	B1	20011113	US 1995-466144	19950606	<--
	US 5968914	A	19991019	US 1995-472210	19950607	<--
	US 6232298	B1	20010515	US 1995-479519	19950607	<--
	US 6274563	B1	20010814	US 1995-479349	19950607	<--
	US 6348451	B1	20020219	US 1995-478736	19950607	<--
	US 6919320	B1	20050719	US 1995-473331	19950607	<--
	US 7166581	B1	20070123	US 1995-473330	19950607	<--
	US 20010025032	A1	20010927	US 1999-249790	19990216	<--
	US 6344447	B2	20020205			
	AU 9952624	A	19991202	AU 1999-52624	19991001	
	US 6743782	B1	20040601	US 2000-494242	20000131	<--
	AU 2002320811	A1	20030403	AU 2002-320811	20021223	
	US 20040033981	A1	20040219	US 2003-601863	20030624	<--
	US 20040192635	A1	20040930	US 2004-824501	20040415	<--
	US 20040220134	A1	20041104	US 2004-855835	20040528	<--
	AU 2005232288	A1	20051201	AU 2005-232288	20051110	
	JP 2006137772	A	20060601	JP 2005-380457	20051228	<--
	JP 2008019268	A	20080131	JP 2007-233452	20070907	<--
PRAI	US 1987-115923	B2	19871028	<--		
	US 1987-115929	B2	19871028	<--		
	US 1989-438493	B2	19890627	<--		
	US 1990-487984	B2	19900205	<--		
	US 1991-724340	B2	19910705	<--		
	US 1992-903107	B2	19920625	<--		
	US 1993-61381	B2	19930514			
	US 1988-186031	B2	19880425	<--		
	EP 1988-910239	A3	19881027	<--		
	JP 1988-509176	A3	19881027	<--		
	JP 1994-303877	A3	19881027	<--		
	JP 2000-379524	A3	19881027	<--		
	US 1989-341925	B1	19890421	<--		
	US 1990-533933	B1	19900605	<--		
	US 1990-438493	B2	19900626	<--		
	US 1991-653882	B2	19910208	<--		
	US 1991-737913	B3	19910729	<--		
	CA 1992-2111571	A3	19920625	<--		
	IN 1992-CA473	A1	19920706	<--		
	US 1992-911379	A3	19920713	<--		
	US 1992-925931	B2	19920807	<--		
	US 1992-958598	B3	19921007	<--		

```
     US 1992-987730         B2    19921208  <--
     US 1992-997657         A3    19921230  <--
     US 1993-96407          B1    19930726
     US 1993-98884          B1    19930729
     US 1993-153163         A1    19931117
     US 1993-158799         B2    19931201
     US 1993-176485         A2    19931230
     US 1994-266897         B3    19940701
     US 1994-289214         A3    19940812
     US 1995-419767         A3    19950410
     US 1995-463740         A1    19950605
     US 1995-472210         A1    19950607
     AU 1995-29150          A3    19950630
     AU 1999-52624          A3    19991001
     US 2000-494242         A3    20000131
     AU 2002-320811         A3    20021223
     JP 2005-380457         A3    20051228
OS   MARPAT 128:266247
RE.CNT  34    THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17  ANSWER 3 OF 13  HCAPLUS  COPYRIGHT 2009 ACS on STN
TI   Methods of reducing toxicity of chemotherapeutic and antiviral agents with
     acylated non-methylated pyrimidine nucleosides
AB   Compds., compns. and methods are disclosed for the treatment and
     prevention of toxicity due to chemotherapeutic agents and antiviral
     agents.  Disclosed are acylated derivs. of non-methylated pyrimidine
     nucleosides.  These compds. are capable of attenuating damage to the
     hematopoietic system in animals receiving antiviral or antineoplastic
     chemotherapy.  Oral administration of triacetyluridine ameliorated the
     hematol. toxicity of 5-fluorouracil.  Triacetyluridine and uridine
     increased the therapeutic index of 5-fluorouracil in tumor-bearing mice.
     Amelioration of the adverse effects of e.g. AZT is also described.
AN   1997:141015  HCAPLUS <<LOGINID::20090528>>
DN   126:139905
OREF 126:26891a
TI   Methods of reducing toxicity of chemotherapeutic and antiviral agents with
     acylated non-methylated pyrimidine nucleosides
IN   Vonborstel, Reid W.; Bamat, Michael K.
PA   Pro-Neuron, Inc., USA
SO   PCT Int. Appl., 142 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 13
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   WO 9640165           A1    19961219    WO 1996-US10067        19960606
         W:  AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE,
             ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS,
             LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD,
             SE, SG
         RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,
             IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN
     IN 177670             A1    19970215    IN 1994-CA701          19940902 <--
     US 5968914            A     19991019    US 1995-472210         19950607 <--
     AU 9661114            A     19961230    AU 1996-61114          19960606
     AU 724805             B2    20000928
     EP 831849             A1    19980401    EP 1996-918461         19960606
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI
```

```
     JP 10511689          T     19981110    JP 1997-502184         19960606
     AU 9952624           A     19991202    AU 1999-52624          19991001
     AU 2002320811        A1    20030403    AU 2002-320811         20021223
     AU 2005232288        A1    20051201    AU 2005-232288         20051110
PRAI US 1995-472210       A     19950607
     US 1987-115923       B2    19871028  <--
     US 1987-115929       B2    19871028  <--
     US 1989-438493       B2    19890627  <--
     US 1990-487984       B2    19900205  <--
     US 1991-724340       B2    19910705  <--
     US 1992-903107       B2    19920625  <--
     IN 1992-CA473        A1    19920706  <--
     US 1993-61381        B2    19930514
     US 1993-176485       A2    19931230
     AU 1995-29150        A3    19950630
     WO 1996-US10067      W     19960606
     AU 1999-52624        A3    19991001
     AU 2002-320811       A3    20021223
RE.CNT  4     THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17  ANSWER 4 OF 13  HCAPLUS  COPYRIGHT 2009 ACS on STN
TI   Pyrimidine nucleotide precursors for treatment of systemic inflammation
     and inflammatory hepatitis
AB   Pyrimidine nucleotide precursors, including acyl derivs. of cytidine,
     uridine, and orotate, and uridine phosphorylase inhibitors, and their use
     in enhancing resistance to sepsis or systemic inflammation, are disclosed.
     Triacetyluridine improved survival of mice treated with a LD of Salmonella
     typhimurium endotoxin, reduced endotoxin-caused tissue damage, reduced
     mortality in viral hepatitis in mice, and improved recovery from ethanol
     intoxication.
AN   1996:205056  HCAPLUS <<LOGINID::20090528>>
DN   124:250921
OREF 124:46221a,46224a
TI   Pyrimidine nucleotide precursors for treatment of systemic inflammation
     and inflammatory hepatitis
IN   Von Borstel, Reid W.; Bamat, Michael K.; Hiltbrand, Bradley M.
PA   Pro-Neuron, Inc., USA
SO   PCT Int. Appl., 95 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 13
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   WO 9601115           A1    19960118    WO 1995-US8259         19950630
         W:  AU, CA, CN, JP, KR, MX
         RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
     IN 177670            A1    19970215    IN 1994-CA701          19940902 <--
     US 5691320           A     19971125    US 1995-465454         19950605 <--
     US 6232298           B1    20010515    US 1995-479519         19950607 <--
     CA 2193967           A1    19960118    CA 1995-2193967        19950630
     CA 2193967           C     20070911
     AU 9529150           A     19960125    AU 1995-29150          19950630
     AU 712679            B2    19991111
     EP 768883            A1    19970423    EP 1995-924764         19950630
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
     CN 1156409           A     19970806    CN 1995-194806         19950630
     JP 10505578          T     19980602    JP 1996-503935         19950630
     CN 101066276         A     20071107    CN 2006-10105555       19950630
     AU 9952624           A     19991202    AU 1999-52624          19991001
```

```
     AU 2002320811        A1    20030403    AU 2002-320811         20021223
     US 20030212036       A1    20031113    US 2003-421831         20030424
     US 20040033981       A1    20040219    US 2003-601863         20030624 <--
     US 20040220134       A1    20041104    US 2004-855835         20040528 <--
     AU 2005232281        A1    20051201    AU 2005-232281         20051110
     AU 2005232286        A1    20051201    AU 2005-232286         20051110
     AU 2005232288        A1    20051201    AU 2005-232288         20051110
     JP 2008007525        A     20080117    JP 2007-250303         20070926
PRAI US 1994-266897       A     19940701
     US 1987-115929       B2    19871028  <--
     US 1989-438493       B2    19890627  <--
     US 1990-438493       B2    19900626  <--
     IN 1992-CA473        A1    19920706  <--
     US 1992-987730       B2    19921208  <--
     US 1993-158799       B2    19931201
     US 1995-463740       A1    19950605
     US 1995-479519       A1    19950607
     AU 1995-29150        A3    19950630
     CN 1995-194806       A3    19950630
     JP 1996-503935       A3    19950630
     WO 1995-US8259       W     19950630
     AU 1999-52624        A3    19991001
     US 2000-702876       A3    20001101
     AU 2002-320811       A3    20021223
RE.CNT  2     THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17  ANSWER 5 OF 13  HCAPLUS  COPYRIGHT 2009 ACS on STN
TI   Acylated pyrimidine nucleosides for treatment of toxicity from
     chemotherapeutic and antiviral agents
AB   The subject invention discloses compds., compns. and methods for treatment
     and prevention of toxicity due to chemotherapeutic agents and antiviral
     agents.  Disclosed are acylated derivs. of non-methylated pyrimidine
     nucleosides.  These compds. are capable of attenuating damage to the
     hematopoietic system in animals receiving antiviral or antineoplastic
     chemotherapy.  Oral administration of triacetyluridine ameliorated the
     hematol. toxicity of 5-fluorouracil.  Effects of other derivs. are also
     presented.  Synthesis of ethoxycarbonyluridine is included.
AN   1995:756200  HCAPLUS <<LOGINID::20090528>>
DN   123:160865
OREF 123:28387a
TI   Acylated pyrimidine nucleosides for treatment of toxicity from
     chemotherapeutic and antiviral agents
IN   Von Borstel, Reid Warren; Bamat, Michael Kevin
PA   Pro-Neuron, Inc., USA
SO   PCT Int. Appl., 143 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 13
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   WO 9426761          A1     19941124    WO 1993-US12689        19931230
         W:  AU, CA, JP, KR
         RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
     AU 9460812          A      19941212    AU 1994-60812          19931230
     IN 177670           A1     19970215    IN 1994-CA701          19940902 <--
     AU 9952624          A      19991202    AU 1999-52624          19991001
     AU 2002320811       A1     20030403    AU 2002-320811         20021223
     AU 2005232288       A1     20051201    AU 2005-232288         20051110
PRAI US 1993-61381       A      19930514
```

	IN 1992-CA473	A1	19920706	<--
	WO 1993-US12689	W	19931230	
	AU 1995-29150	A3	19950630	
	AU 1999-52624	A3	19991001	
	AU 2002-320811	A3	20021223	

OS MARPAT 123:160865
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 6 OF 13 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Preparation of nucleic acid-related compounds
GI





AB Nucleoside N-(thio)phosphoramidate derivs. [I; R1, R2 = H, OH; Z = Q - Q2; X = O, S, Se; R4, R5 = OH, NH2, (un)substituted C1-18 alkoxy or aryloxy], useful as pharmaceuticals, agrochems., and medical diagnostic agents (no data), are prepared Thus, 1,2,4-1H-triazole was dissolved in acetone and reacted with P(O)Cl3 and Et3N at 0° for 30 min and then with a solution of 2',3',5'-tri-O-benzoyladenosine in MeCN to give 80% triethylammonium 2',3',5'-tri-O-benzoyladenosine-6-N-(triazolyl)phosphoramidate, which was treated with concentrated aqueous NH3-pyridine
mixture to give, after purification by anion exchange chromatog. using DEA cellulose and lyophilization, 83% triethylammonium adenosine-6-N-(amino)phosphoramidate.

AN 1994:324143 HCAPLUS <<LOGINID::20090528>>
DN 120:324143
OREF 120:57057a,57060a
TI Preparation of nucleic acid-related compounds
IN Sekine, Mitsuo; Wada, Takeshi
PA Wako Pure Chem Ind Ltd, Japan
SO Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI JP 06009681 A 19940118 JP 1993-76085 19930310 <--
PRAI JP 1992-88134 A1 19920312 <--
OS MARPAT 120:324143

L17 ANSWER 7 OF 13 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Preparation and therapeutic used of acylated uridine and cytidine.
GI



AB Acylated pyrimidine nucleosides [I; B = Q where R4 = H; R1, R2, R3 = acyl residue of C5-22 unbranched fatty acid, amino acids (e.g. glycine, L-alanine, and L-lysine), C3-22 dicarboxylic acids, carboxylic acids (e.g. glycolic acid, pyruvic acid, and lactic acid)] (II) and I (B = Q; R1 - R3 = H, acyl radical of a metabolite; R4 = acyl radical of a metabolite] (III) and therapeutic uses of I (B = Q, Q1), e.g. for treating hepatopathies, diabetes, and heart disease, are described. In general, 2',3',5'-tri-O-acyluridines were prepared by heating a solution of 1 g uridine and 3.1 molar equivalent acid anhydride (e.g., Ac2O or butyric anhydride) in anhydrous pyridine at 80-85° for 2 h. A mixture of 2',3',5'-tri-O-acetylcytidine (IV) and -uridine(V) at 590 mg/kg of each administered to rats immediately after, and 1 and 20 h after aorta constriction and administration of isoproterenol (5 mg/kg) significantly restored myocardial performance.
AN 1989:595338 HCAPLUS <<LOGINID::20090528>>
DN 111:195338
OREF 111:32487a,32490a
TI Preparation and therapeutic used of acylated uridine and cytidine.
IN Von Borstel, Reid Warren; Bamat, Michael Kevin
PA Pro-Neuron, Inc., USA
SO PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 8903837	A1	19890505	WO 1988-US3823	19881027	<--
	W: AU, BR, DK, FI, JP, KR, NO, SU, US					
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE					
	AU 8927899	A	19890523	AU 1989-27899	19881027	<--
	EP 339075	A1	19891102	EP 1988-909932	19881027	<--
	EP 339075	B1	19930818			
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE					
	JP 02500372	T	19900208	JP 1988-509176	19881027	<--
	JP 2894610	B2	19990524			
	CA 1321994	C	19930907	CA 1988-581429	19881027	<--
	AT 93236	T	19930915	AT 1988-909932	19881027	<--
	JP 10001436	A	19980106	JP 1997-36734	19881027	<--
	JP 3474073	B2	20031208			
	JP 2001192335	A	20010717	JP 2000-379524	19881027	<--

	IN 167680	A1	19901208	IN 1988-MA755	19881028	<--
	IL 88208	A	19961016	IL 1988-88208	19881028	<--
	ZA 8900232	A	19900627	ZA 1989-232	19890111	<--
	US 5583117	A	19961210	US 1993-140475	19931025	<--
	IN 177670	A1	19970215	IN 1994-CA701	19940902	<--
	JP 07228535	A	19950829	JP 1994-303877	19941207	<--
	US 5691320	A	19971125	US 1995-465454	19950605	<--
	US 6329350	B1	20011211	US 1995-464939	19950605	<--
	US 7173017	B1	20070206	US 1995-465455	19950605	<--
	US 6258795	B1	20010710	US 1995-466145	19950606	<--
	US 6316426	B1	20011113	US 1995-466144	19950606	<--
	US 6232298	B1	20010515	US 1995-479519	19950607	<--
	US 6274563	B1	20010814	US 1995-479349	19950607	<--
	AU 9952624	A	19991202	AU 1999-52624	19991001	
	US 20020035086	A1	20020321	US 2001-964514	20010928	<--
	US 7105498	B2	20060912			
	AU 2002320811	A1	20030403	AU 2002-320811	20021223	
	US 20040033981	A1	20040219	US 2003-601863	20030624	<--
	US 20040220134	A1	20041104	US 2004-855835	20040528	<--
	AU 2005232288	A1	20051201	AU 2005-232288	20051110	
	JP 2006137772	A	20060601	JP 2005-380457	20051228	<--
	JP 2008019268	A	20080131	JP 2007-233452	20070907	<--
PRAI	US 1987-115929	A2	19871028	<--		
	EP 1988-909932	A	19881027	<--		
	JP 1988-509176	A3	19881027	<--		
	JP 1994-303877	A3	19881027	<--		
	JP 2000-379524	A3	19881027	<--		
	WO 1988-US3823	A	19881027	<--		
	US 1989-438493	B2	19890627	<--		
	US 1990-438493	B2	19900626	<--		
	US 1991-737913	B3	19910729	<--		
	IN 1992-CA473	A1	19920706	<--		
	US 1992-987730	B2	19921208	<--		
	US 1992-997657	A3	19921230	<--		
	US 1993-158799	B2	19931201			
	US 1994-266897	B3	19940701			
	US 1995-463740	A1	19950605			
	US 1995-466144	A3	19950606			
	AU 1995-29150	A3	19950630			
	AU 1999-52624	A3	19991001			
	AU 2002-320811	A3	20021223			
	JP 2005-380457	A3	20051228			

OS MARPAT 111:195338

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 8 OF 13 HCAPLUS COPYRIGHT 2009 ACS on STN

TI N4-Chloroacetylcytosine arabinoside - a possible prodrug of cytosine arabinoside

GI



I

AB Lipophilic N1-acetyl and N4-chloroacetyl derivs. (I, R = H, ribosyl, 2-deoxyribosyl or arabinosyl, R1 = H or Cl) of cytidine, 2'-deoxycytidine and cytosine arabinoside (Ara-C) were prepared by acetylation and chloroacetylation, resp. Their toxicity to A(Ti)Cl-3 hamster fibrosarcoma cells was determined I (R1 = ribosyl, 2-deoxyribosyl or arabinosyl, R1 = Cl) were potent with no colonies surviving at concns. of 10-4, 10-4, and 10-6M, resp. I (R1 = ribosyl, 2-deoxyribosyl or arabinosyl, R1 = H) showed comparatively poor toxicity with 95, 77 and 87% survival of colonies, resp. N4-Chloroacetyl-2'-deoxycytidine and N4-chloroacetyl-Ara-C underwent hydrolysis in phosphate-buffered saline at 50° to yield the parent nucleosides and the N3-carboxymethyl derivs. via 1-H-2,3-dihydro-2,5-dioxoimidazo[1,2-c]pyrimidines.
AN 1988:142952 HCAPLUS <<LOGINID::20090528>>
DN 108:142952
OREF 108:23279a,23282a
TI N4-Chloroacetylcytosine arabinoside - a possible prodrug of cytosine arabinoside
AU Ariatti, Mario; Jones, Peter A.
CS Dep. Biochem., Univ. Durban-Westville, Durban, 4000, S. Afr.
SO Biochemistry International (1987), 15(6), 1097-103
CODEN: BIINDF; ISSN: 0158-5231
DT Journal
LA English

L17 ANSWER 9 OF 13 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Platinum-dioxopyrimidine complexes
AB Complexes of 2,4-dioxopyrimidines with cis-diaquodiamineplatinum (II) were prepared and tested for antitumor, antibacterial and antiviral activity. The complexes appear to have good activity with low renal toxicity.
AN 1984:114992 HCAPLUS <<LOGINID::20090528>>
DN 100:114992
OREF 100:17361a,17364a
TI Platinum-dioxopyrimidine complexes
IN Rosenberg, Barnett; Van Camp, Loretta; Ficher, Robert G.; Kansy, Samir; Peresie, Henry J.; Davidson, James P.
PA Research Corp. , USA
SO U.S., 11 pp. Cont. of U.S. Ser. No. 803,269, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 4419351	A	19831206	US 1978-970524	19781218 <--
PRAI US 1974-508854	A1	19740924	<--	
US 1977-803269	A1	19770603	<--	

OS MARPAT 100:114992

L17 ANSWER 10 OF 13 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Platinum-(2,4-dioxopyrimidine) complex
AB The title complexes were prepared by treating 2,4-dioxopyrimidine derivs. with cis-diaquadiammineplatinum(II) [20115-64-4] in a 2:1 to 1:1 mole ratio at 0-55°. The complexes showed antitumor, antiviral, and antibacterial activity, high water solubility, and low renal toxicity. For example, 0.01 mole cis-dichlorodiammineplatinum(II) [15663-27-1] was treated with 0.02 mole AgNO3 in the dark to give cis-diaquadiammineplatinum(II). This complex was then treated with uracil in a 1:1 mole ratio at pH 6-7 to give a complex which showed antitumor, antibacterial, and antiviral activity.

AN 1976:428777 HCAPLUS <<LOGINID::20090528>>
DN 85:28777
OREF 85:4645a,4648a
TI Platinum-(2,4-dioxopyrimidine) complex
IN Rosenberg, Barnett; Mansy, Samir A. L. A.; Van Camp, Loretta L.; Peresie, Henry J.; Fischer, Robert George; Davidson, James P.
PA Research Corp., USA
SO Ger. Offen., 51 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 2445418	A1	19760401	DE 1974-2445418	19740923 <--
JP 58028278	B	19830615	JP 1974-112688	19740930 <--
PRAI DE 1974-2445418		19740923	<--	

L17 ANSWER 11 OF 13 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Cytidine mosinate
GI For diagram(s), see printed CA Issue.
AB Cytidine 5'-inosinate (I) [33156-26-2], useful in the formation of cellular matter, was prepared from cytidine (or its sulfate) and 5'-inosinic acid (or its Na salt).
AN 1976:49831 HCAPLUS <<LOGINID::20090528>>
DN 84:49831
OREF 84:8151a,8154a
TI Cytidine mosinate
PA Fabrica Espanola de Productos Quimicos y Farmaceuticos S. A., Spain
SO Span., 5 pp.
CODEN: SPXXAD
DT Patent
LA Spanish
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI ES 406066	A1	19750816	ES 1972-406066	19720824 <--
PRAI ES 1972-406066	A	19720824	<--	

L17 ANSWER 12 OF 13 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Platinum-pyrimidine blues and related complexes. New class of potent antitumor agents
AB Many of the complexes of diaquo species of cis-dichlorodiammineplatinum (II) and pyrimidines and substituted pyrimidines showed superior activity against the ascites Sarcoma 180 tumor in mice when compared to cis-dichlorodiammineplatinum [15663-27-1]. Activity was also shown against the Rauscher leukemia, Ehrlich ascites, and ADJ/PC6A tumors. The platinum-uracil complex caused only minor focal damage to the proximal convoluted tubules of the kidney. The methods for synthesis and characterization of some of the complexes are described, though the structure of the complexes are largely uncertain at this time.
AN 1975:508573 HCAPLUS <<LOGINID::20090528>>
DN 83:108573
OREF 83:16985a,16988a
TI Platinum-pyrimidine blues and related complexes. New class of potent antitumor agents
AU Davidson, James P.; Faber, Paula J.; Fischer, Robert G., Jr.; Mansy, Samir; Peresie, Henry J.; Rosenberg, Barnett; VanCamp, Loretta
CS Dep. Biophys., Michigan State Univ., East Lansing, MI, USA
SO Cancer Chemotherapy Reports, Part 1 (1975), 59(2), 287-300
CODEN: CCROBU; ISSN: 0576-6559

```
DT   Journal
LA   English

L17  ANSWER 13 OF 13  HCAPLUS  COPYRIGHT 2009 ACS on STN
TI   Aminoacyl nucleosides derived from the tumor inhibitor,
     1-aminocyclopentanecarboxylic acid
AB   The 2'(3')-O-adenosine and -uridine esters of
     1-aminocyclopen-tanecarboxylic acid have been prepared  They had no
     significant effect against an exptl. plasma cell tumor in mice, nor did
     they inhibit protein synthesis in vitro.  Each aminoacyl derivative was
separated
     into its 2 components, which were characterized by N.M.R. spectroscopy.
     No interconversion between the 2'- and 3'-substituted nucleosides
     occurred, although base-catalyzed hydrolysis proceeded at a rate
     comparable with that of other aminoacyl nucleosides.  The possible
     implications of these findings in protein biosynthesis are discussed.
     Some related compds. derived from 6-(methylthio)purine are described.
AN   1969:522249  HCAPLUS <<LOGINID::20090528>>
DN   71:122249
OREF 71:22713a,22716a
TI   Aminoacyl nucleosides derived from the tumor inhibitor,
     1-aminocyclopentanecarboxylic acid
AU   Jarman, Michael; Kuszmann, J.; Stock, J. A.
CS   Roy. Cancer Hosp., London, UK
SO   Biochemical Pharmacology (1969), 18(10), 2473-84
     CODEN: BCPCA6; ISSN: 0006-2952
DT   Journal
LA   English


=> d his


     (FILE 'HOME' ENTERED AT 12:37:09 ON 28 MAY 2009)

     FILE 'REGISTRY' ENTERED AT 12:37:15 ON 28 MAY 2009
                EXP TRIACETYLCYTIDINE/CN

     FILE 'STNGUIDE' ENTERED AT 12:37:29 ON 28 MAY 2009

     FILE 'HCAPLUS' ENTERED AT 12:42:38 ON 28 MAY 2009
L1           52 S TRIACETYLCYTIDINE OR TRIACETYLURIDINE OR ETHOXYCARBONYLURIDIN

     FILE 'STNGUIDE' ENTERED AT 12:43:00 ON 28 MAY 2009

     FILE 'HCAPLUS' ENTERED AT 12:43:44 ON 28 MAY 2009
L2        24237 S FLUOROURACIL OR FLUOROOROTATE OF TEGAFUR OR FLUOROURIDINE OR
L3         9003 S (ARABINOSYL(2A)CYTOSINE) OR CYCLOCYTIDINE OR (AZA(2A)CYTIDINE
L4        66014 S AZARIBINE OR THYMIDINE OR DEAZAURIDINE OR DIDEOXYCYTIDINE OR
L5           15 S L1 AND (L2 OR L3 OR L4)
L6           34 S L1 AND (PY<1993 OR AY<1993 OR PRY<1993)
L7            9 S L5 AND (PY<1993 OR AY<1993 OR PRY<1993)

     FILE 'STNGUIDE' ENTERED AT 12:43:54 ON 28 MAY 2009

     FILE 'HCAPLUS' ENTERED AT 12:44:02 ON 28 MAY 2009

     FILE 'STNGUIDE' ENTERED AT 12:44:04 ON 28 MAY 2009

     FILE 'HCAPLUS' ENTERED AT 12:48:14 ON 28 MAY 2009
L8           25 S L6 NOT L7
```

```
     FILE 'STNGUIDE' ENTERED AT 12:48:29 ON 28 MAY 2009

     FILE 'HCAPLUS' ENTERED AT 12:50:14 ON 28 MAY 2009

     FILE 'STNGUIDE' ENTERED AT 12:50:18 ON 28 MAY 2009

     FILE 'REGISTRY' ENTERED AT 12:50:41 ON 28 MAY 2009
                EXP 2,3,5 TRIACETYLURIDINE/CN
                EXP 2,3,5-TRIACETYLURIDINE/CN
                EXP ETHOXYCARBONYLURIDINE/CN
L9              STRUCTURE UPLOADED
L10           50 S L9
L11         1403 S L9 SSS FULL
                EXP URIDINE/CN
L12            1 S E3
L13            1 S CYTIDINE/CN
L14         1401 S L11 NOT (L12 OR L13)

     FILE 'HCAPLUS' ENTERED AT 13:18:56 ON 28 MAY 2009
L15          100 S L14/THU
L16         1204 S L14 AND (PY<1993 OR AY<1993 OR PRY<1993)
L17           13 S L15 AND (PY<1993 OR AY<1993 OR PRY<1993)

=> log hold

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      41.85     316.92

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                     -10.66     -24.60

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 13:19:32 ON 28 MAY 2009

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'HCAPLUS' AT 13:45:21 ON 28 MAY 2009
FILE 'HCAPLUS' ENTERED AT 13:45:21 ON 28 MAY 2009
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      41.85     316.92

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                     -10.66     -24.60

=> s uridine or cytidine
```

```
         29583 URIDINE
         14286 CYTIDINE
L18      38607 URIDINE OR CYTIDINE

=> s l18 and (L2 or L3 or L4)
L19       8772 L18 AND (L2 OR L3 OR L4)

=> s l19 and 9PY<1993 or AY<1993 or PRY<1993)
UNMATCHED RIGHT PARENTHESIS 'PRY<1993)'
The number of right parentheses in a query must be equal to the
number of left parentheses.

=> s l19 and (PY<1993 or AY<1993 or PRY<1993)
      14940497 PY<1993
       2629968 AY<1993
       2070996 PRY<1993
L20       6282 L19 AND (PY<1993 OR AY<1993 OR PRY<1993)

=> s toxicity or (side effect)
        383836 TOXICITY
        722294 SIDE
       5143236 EFFECT
         16486 SIDE EFFECT
                (SIDE(W)EFFECT)
L21     397890 TOXICITY OR (SIDE EFFECT)

=> s l20 and l21
L22        269 L20 AND L21

=> file stnguide
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    47.55     322.62

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -10.66     -24.60

FILE 'STNGUIDE' ENTERED AT 13:46:29 ON 28 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 22, 2009 (20090522/UP).

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.07     322.69

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00     -24.60

FILE 'REGISTRY' ENTERED AT 13:46:36 ON 28 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.
```

```
STRUCTURE FILE UPDATES:   26 MAY 2009  HIGHEST RN 1149431-57-1
DICTIONARY FILE UPDATES:  26 MAY 2009  HIGHEST RN 1149431-57-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> exp cytidine/cn
E1            1     CYTIDIN-5'-C-YL, 2'-DEOXY-/CN
E2            1     CYTIDIN-5'-C-YL, 2'-DEOXY-, 5'-(DIHYDROGEN PHOSPHATE)/CN
E3            1 --> CYTIDINE/CN
E4            3     CYTIDINE (2'-DEOXYCYTIDYLYL-(3'.FWDARW.5')-2'-DEOXYADENYLYL-
                    (3'.FWDARW.5')-2'-DEOXYADENYLYL-(3'.FWDARW.5')-2'-DEOXYADENY
                    LYL-(3'.FWDARW.5')-2'-DEOXYADENYLYL-(3'.FWDARW.5')-2'-DEOXYA
                    DENYLYL-(3'.FWDARW.5/CN
E5            1     CYTIDINE (TETRAHYDROGEN TRIPHOSPHATE), 5-CHLORO-/CN
E6            1     CYTIDINE / DEOXYCYTIDYLATE DEAMINASE FAMILY PROTEIN (ACINETO
                    BACTER STRAIN ADP1)/CN
E7            1     CYTIDINE / DEOXYCYTIDYLATE DEAMINASE FAMILY PROTEIN (XANTHOM
                    ONAS CAMPESTRIS VESICATORIA STRAIN 85-10)/CN
E8            1     CYTIDINE 2',3'-CYCLIC MONOPHOSPHATE/CN
E9            1     CYTIDINE 2',3'-CYCLIC PHOSPHATE SODIUM SALT/CN
E10           1     CYTIDINE 2',3'-CYCLOPHOSPHATE/CN
E11           1     CYTIDINE 2',3'-DIPHOSPHATE/CN
E12           1     CYTIDINE 2',3'-DISULFATE DISODIUM SALT/CN

=> file hcpalus
'HCPALUS' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'REGISTRY'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.

=> s (l12 or L13) and (L2-L4)
          216 FLUOROURACIL
            2 FLUOROOROTATE
       147896 OF
            4 TEGAFUR
            0 FLUOROOROTATE OF TEGAFUR
                (FLUOROOROTATE(W)OF(W)TEGAFUR)
          484 FLUOROURIDINE
           88 FLUOROCYTIDINE
            0 FLUORONUCLEOSIDE
      2173513 TRIFLUOROMETHYL
         1191 DEOXYURIDINE
           11 TRIFLUOROMETHYL (2A) DEOXYURIDINE
          623 ARABINOSYL
         2691 CYTOSINE
           30 ARABINOSYL(2A)CYTOSINE
```

```
           27 CYCLOCYTIDINE
       995117 AZA
        30556 CYTIDINE
           93 AZA(2A)CYTIDINE
           69 AZACYTIDINE
           24 AZACYTOSINE
           72 PALA
           14 AZT
            6 PYRAZOFURIN
           55 AZAURIDINE
            1 AZARIBINE
        36923 THYMIDINE
           11 DEAZAURIDINE
           69 DIDEOXYCYTIDINE
         1191 DEOXYURIDINE
            8 ARABINOSYLURACIL
          118 DIDEOXYURIDINE
L23           0 (L12 OR L13) AND ((L2 OR L3 OR L4))

=> s (l12/thu or L13/thu)
FIELD CODES CANNOT BE CHANGED HERE
You may have tried to apply a field code to a term that already has a
field code.  You can only add a field code to a term that has no field
code appended to it.

=> s l12/thu
FIELD CODES CANNOT BE CHANGED HERE
You may have tried to apply a field code to a term that already has a
field code.  You can only add a field code to a term that has no field
code appended to it.

=> s l12
L24           1 URIDINE/CN

=> file hcaplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   151.24     473.93

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00     -24.60

FILE 'HCAPLUS' ENTERED AT 13:48:10 ON 28 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 28 May 2009  VOL 150 ISS 22
FILE LAST UPDATED: 27 May 2009  (20090527/ED)
```

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2009

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

```
=> s (l12/thu or L13/thu)
          7463 L12
       1128974 THU/RL
           324 L12/THU
                 (L12 (L) THU/RL)
          4592 L13
       1128974 THU/RL
           175 L13/THU
                 (L13 (L) THU/RL)
L25        411 (L12/THU OR L13/THU)

=> s l25 and (L2-L4)
L26        164 L25 AND ((L2 OR L3 OR L4))

=> s l26 and (PY<1993 or AY<1993 or PRY<1993)
      14940497 PY<1993
       2629968 AY<1993
       2070996 PRY<1993
L27         22 L26 AND (PY<1993 OR AY<1993 OR PRY<1993)

=> d l27 1-22 ti abs bib

L27  ANSWER 1 OF 22  HCAPLUS  COPYRIGHT 2009 ACS on STN
TI   Antidote delivery for reducing side effects of a drug
AB   Method for reducing side-effects of a drug caused by undesired effects of
     said drug upon body cells which are not the intended target of said drug
     comprising the preferential delivery of antidote for said drug to said
     body cells when said drug is used, said preferential delivery effected by
     attaching to said antidote antibody with affinity for said body cells.
     Liposomes bound to antibodies with affinity to bone marrow precursors of
     white blood corpuscles are injected i.v. several h prior to the
     administration of methotrexate.
AN   2002:696462  HCAPLUS <<LOGINID::20090528>>
DN   137:222094
TI   Antidote delivery for reducing side effects of a drug
IN   Matsumura, Kenneth N.
PA   USA
SO   U.S. Pat. Appl. Publ., 8 pp., Cont.-in-part of U.S. Ser. No. 322,209,
     abandoned.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ----------------    ----   --------    --------------------   --------
PI   US 20020127223      A1     20020912    US 2001-906322         20010713 <--
PRAI US 1984-631806      B2     19840717  <--
     US 1987-7763        B2     19870127  <--
```

US 1989-322209 B2 19890313 <--

L27 ANSWER 2 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Preparation of transition-state iminoribitols as inhibitors for nucleoside hydrolase and transferase reactions
GI



I

AB This invention is directed to transition-state analog iminoribitols I wherein R1 is hydrogen, phosphoryl, mononucleotide in phosphodiester bonding to the oxygen of R1--O, or polynucleotide in phosphodiester bonding to the oxygen of R1--O; R2 is hydrogen, phosphoryl, mononucleotide in phosphodiester bonding to the oxygen of R1--O, or polynucleotide in phosphodiester bonding to the oxygen of R1--O; R3 is hydrogen or hydroxy, R4 is hydrogen or hydroxy; and R5 is hydrogen, Ph, pyridyl, imidazolyl, adenine, guanine, pyrimidine, or an ortho, meta or para substituted Ph.and to the use of said compds. as inhibitors of nucleoside hydrolase and transferase enzyme activity of parasites. This invention is further directed to the use of said compds. to treat infections and diseases caused by certain bacterial and plant toxins. Thus, I (R1 = R2 = R4 = H; R3 = OH; R5 = Ph) was prepared and tested as nucleoside hydrolase inhibitor (Ki = 0.30 μM).
AN 2000:658499 HCAPLUS <<LOGINID::20090528>>
DN 133:222970
TI Preparation of transition-state iminoribitols as inhibitors for nucleoside hydrolase and transferase reactions
IN Schramm, Vern L.; Horenstein, Benjamin
PA Albert Einstein College of Medicine of Yeshiva University, USA
SO U.S., 37 pp., Cont.-in-part of U.S. Ser. No. 781,745, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6121296	A	20000919	US 1998-17097	19980202 <--
PRAI US 1992-971871	B1	19921104	<--	
US 1995-427730	B1	19950424		
US 1997-781745	B2	19970110		

OS MARPAT 133:222970
RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 3 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
AB Compds., comps., and methods are disclosed for treatment and prevention of toxicity due to chemotherapeutic agents and antiviral agents. Disclosed are acylated derivs. of nonmethylated pyrimidine nucleosides.

These compds. are capable of attenuating damage to the hematopoietic system in animals receiving antiviral or antineoplastic chemotherapy.

AN 1999:670113 HCAPLUS <<LOGINID::20090528>>

DN 131:281604

TI Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides

IN Von Borstel, Reid; Bamat, Michael K.

PA Pro-Neuron, Inc., USA

SO U.S., 31 pp., Cont.-in-part U. S. Ser. 176,485.
CODEN: USXXAM

DT Patent

LA English

FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 5968914	A	19991019	US 1995-472210	19950607	<--
	EP 712629	A1	19960522	EP 1995-203050	19881027	<--
	EP 712629	B1	20030618			
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE					
	JP 10001436	A	19980106	JP 1997-36734	19881027	<--
	JP 3474073	B2	20031208			
	JP 2001192335	A	20010717	JP 2000-379524	19881027	<--
	CA 2111571	A1	19930121	CA 1992-2111571	19920625	<--
	CA 2111571	C	20050823			
	CA 2504078	A1	19930121	CA 1992-2504078	19920625	<--
	CA 2504078	C	20070828			
	ES 2160579	T3	20011116	ES 1992-914215	19920625	<--
	ZA 9204975	A	19930428	ZA 1992-4975	19920703	<--
	IN 175688	A1	19950812	IN 1992-CA473	19920706	<--
	US 5246708	A	19930921	US 1992-911379	19920713	<--
	US 5470838	A	19951128	US 1992-997657	19921230	<--
	US 5583117	A	19961210	US 1993-140475	19931025	<--
	US 6020320	A	20000201	US 1993-153163	19931117	<--
	US 5736531	A	19980407	US 1993-176485	19931230	<--
	IN 177670	A1	19970215	IN 1994-CA701	19940902	<--
	US 5770582	A	19980623	US 1995-419767	19950410	<--
	US 5691320	A	19971125	US 1995-465454	19950605	<--
	US 6054441	A	20000425	US 1995-463790	19950605	<--
	US 6060459	A	20000509	US 1995-465016	19950605	<--
	US 7307166	B1	20071211	US 1995-463771	19950605	<--
	US 6258795	B1	20010710	US 1995-466145	19950606	<--
	US 6316426	B1	20011113	US 1995-466144	19950606	<--
	US 6232298	B1	20010515	US 1995-479519	19950607	<--
	US 6274563	B1	20010814	US 1995-479349	19950607	<--
	US 6348451	B1	20020219	US 1995-478736	19950607	<--
	US 6919320	B1	20050719	US 1995-473331	19950607	<--
	CA 2223640	A1	19961219	CA 1996-2223640	19960606	
	WO 9640165	A1	19961219	WO 1996-US10067	19960606	
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG					
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN					
	AU 9661114	A	19961230	AU 1996-61114	19960606	
	AU 724805	B2	20000928			
	EP 831849	A1	19980401	EP 1996-918461	19960606	
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI					
	CN 1192149	A	19980902	CN 1996-195929	19960606	
	JP 10511689	T	19981110	JP 1997-502184	19960606	

	JP 2003201240	A	20030718	JP 2003-721	19960606	
	EP 1491201	A1	20041229	EP 2004-23557	19960606	
	EP 1491201	B1	20060322			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, AL					
	AT 320813	T	20060415	AT 2004-23557	19960606	
	ES 2257721	T3	20060801	ES 2004-23557	19960606	
	HK 1072897	A1	20060512	HK 2005-105421	19981003	
	US 20010025032	A1	20010927	US 1999-249790	19990216	<--
	US 6344447	B2	20020205			
	AU 9952624	A	19991202	AU 1999-52624	19991001	
	US 6743782	B1	20040601	US 2000-494242	20000131	<--
	AU 2002320811	A1	20030403	AU 2002-320811	20021223	
	US 20040033981	A1	20040219	US 2003-601863	20030624	<--
	US 20040192635	A1	20040930	US 2004-824501	20040415	<--
	US 20040220134	A1	20041104	US 2004-855835	20040528	<--
	AU 2005232288	A1	20051201	AU 2005-232288	20051110	
	JP 2006137772	A	20060601	JP 2005-380457	20051228	<--
	JP 2008019268	A	20080131	JP 2007-233452	20070907	<--
PRAI	US 1987-115923	B2	19871028	<--		
	US 1987-115929	B2	19871028	<--		
	US 1989-438493	B2	19890627	<--		
	US 1990-487984	B2	19900205	<--		
	US 1991-724340	B2	19910705	<--		
	US 1992-903107	B2	19920625	<--		
	US 1993-61381	B2	19930514			
	US 1993-176485	A2	19931230			
	US 1988-186031	B2	19880425	<--		
	EP 1988-910239	A3	19881027	<--		
	JP 1988-509176	A3	19881027	<--		
	JP 1994-303877	A3	19881027	<--		
	JP 2000-379524	A3	19881027	<--		
	US 1989-341925	B1	19890421	<--		
	US 1990-533933	B1	19900605	<--		
	US 1990-438493	B2	19900626	<--		
	US 1991-653882	B2	19910208	<--		
	US 1991-737913	B3	19910729	<--		
	CA 1992-2111571	A3	19920625	<--		
	IN 1992-CA473	A1	19920706	<--		
	US 1992-911379	A3	19920713	<--		
	US 1992-925931	B2	19920807	<--		
	US 1992-958598	B3	19921007	<--		
	US 1992-987730	B2	19921208	<--		
	US 1992-997657	A3	19921230	<--		
	US 1993-96407	B1	19930726			
	US 1993-98884	B1	19930729			
	US 1993-153163	A1	19931117			
	US 1993-158799	B2	19931201			
	US 1994-266897	B3	19940701			
	US 1994-289214	A3	19940812			
	US 1995-419767	A3	19950410			
	US 1995-463740	A1	19950605			
	US 1995-472210	A	19950607			
	AU 1995-29150	A3	19950630			
	EP 1996-918461	A3	19960606			
	JP 1997-502184	A3	19960606			
	WO 1996-US10067	W	19960606			
	HK 1998-111095	A3	19981003			
	AU 1999-52624	A3	19991001			
	US 2000-494242	A3	20000131			
	AU 2002-320811	A3	20021223			

JP 2005-380457 A3 20051228
RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 4 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
AB The subject invention discloses compds., compns. and methods for treatment and prevention of toxicity due to chemotherapeutic agents and antiviral agents. Disclosed are acylated derivs. of non-methylated pyrimidine nucleosides. These compds. are capable of attenuating damage to the hematopoietic system in animals receiving antiviral or antineoplastic chemotherapy. Thus, biol activity of 5-fluorouracil is reported.
AN 1998:236253 HCAPLUS <<LOGINID::20090528>>
DN 128:266247
OREF 128:52559a,52562a
TI Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
IN Von Borstel, Reid W.; Bamat, Michael K.
PA Pro-Neuron, Inc., USA
SO U.S., 26 pp., Cont.-in-part of U.S. Ser. No. 61,381, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 13

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5736531	A	19980407	US 1993-176485	19931230 <--
	EP 712629	A1	19960522	EP 1995-203050	19881027 <--
	EP 712629	B1	20030618		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 10001436	A	19980106	JP 1997-36734	19881027 <--
	JP 3474073	B2	20031208		
	JP 2001192335	A	20010717	JP 2000-379524	19881027 <--
	CA 2111571	A1	19930121	CA 1992-2111571	19920625 <--
	CA 2111571	C	20050823		
	CA 2504078	A1	19930121	CA 1992-2504078	19920625 <--
	CA 2504078	C	20070828		
	ES 2160579	T3	20011116	ES 1992-914215	19920625 <--
	ZA 9204975	A	19930428	ZA 1992-4975	19920703 <--
	IN 175688	A1	19950812	IN 1992-CA473	19920706 <--
	US 5246708	A	19930921	US 1992-911379	19920713 <--
	US 5470838	A	19951128	US 1992-997657	19921230 <--
	US 5583117	A	19961210	US 1993-140475	19931025 <--
	US 6020320	A	20000201	US 1993-153163	19931117 <--
	IN 177670	A1	19970215	IN 1994-CA701	19940902 <--
	US 5770582	A	19980623	US 1995-419767	19950410 <--
	US 5691320	A	19971125	US 1995-465454	19950605 <--
	US 6054441	A	20000425	US 1995-463790	19950605 <--
	US 6060459	A	20000509	US 1995-465016	19950605 <--
	US 7307166	B1	20071211	US 1995-463771	19950605 <--
	US 6258795	B1	20010710	US 1995-466145	19950606 <--
	US 6316426	B1	20011113	US 1995-466144	19950606 <--
	US 5968914	A	19991019	US 1995-472210	19950607 <--
	US 6232298	B1	20010515	US 1995-479519	19950607 <--
	US 6274563	B1	20010814	US 1995-479349	19950607 <--
	US 6348451	B1	20020219	US 1995-478736	19950607 <--
	US 6919320	B1	20050719	US 1995-473331	19950607 <--
	US 7166581	B1	20070123	US 1995-473330	19950607 <--
	US 20010025032	A1	20010927	US 1999-249790	19990216 <--

	US 6344447	B2	20020205			
	AU 9952624	A	19991202	AU 1999-52624	19991001	
	US 6743782	B1	20040601	US 2000-494242	20000131	<--
	AU 2002320811	A1	20030403	AU 2002-320811	20021223	
	US 20040033981	A1	20040219	US 2003-601863	20030624	<--
	US 20040192635	A1	20040930	US 2004-824501	20040415	<--
	US 20040220134	A1	20041104	US 2004-855835	20040528	<--
	AU 2005232288	A1	20051201	AU 2005-232288	20051110	
	JP 2006137772	A	20060601	JP 2005-380457	20051228	<--
	JP 2008019268	A	20080131	JP 2007-233452	20070907	<--
PRAI	US 1987-115923	B2	19871028	<--		
	US 1987-115929	B2	19871028	<--		
	US 1989-438493	B2	19890627	<--		
	US 1990-487984	B2	19900205	<--		
	US 1991-724340	B2	19910705	<--		
	US 1992-903107	B2	19920625	<--		
	US 1993-61381	B2	19930514			
	US 1988-186031	B2	19880425	<--		
	EP 1988-910239	A3	19881027	<--		
	JP 1988-509176	A3	19881027	<--		
	JP 1994-303877	A3	19881027	<--		
	JP 2000-379524	A3	19881027	<--		
	US 1989-341925	B1	19890421	<--		
	US 1990-533933	B1	19900605	<--		
	US 1990-438493	B2	19900626	<--		
	US 1991-653882	B2	19910208	<--		
	US 1991-737913	B3	19910729	<--		
	CA 1992-2111571	A3	19920625	<--		
	IN 1992-CA473	A1	19920706	<--		
	US 1992-911379	A3	19920713	<--		
	US 1992-925931	B2	19920807	<--		
	US 1992-958598	B3	19921007	<--		
	US 1992-987730	B2	19921208	<--		
	US 1992-997657	A3	19921230	<--		
	US 1993-96407	B1	19930726			
	US 1993-98884	B1	19930729			
	US 1993-153163	A1	19931117			
	US 1993-158799	B2	19931201			
	US 1993-176485	A2	19931230			
	US 1994-266897	B3	19940701			
	US 1994-289214	A3	19940812			
	US 1995-419767	A3	19950410			
	US 1995-463740	A1	19950605			
	US 1995-472210	A1	19950607			
	AU 1995-29150	A3	19950630			
	AU 1999-52624	A3	19991001			
	US 2000-494242	A3	20000131			
	AU 2002-320811	A3	20021223			
	JP 2005-380457	A3	20051228			

OS MARPAT 128:266247
RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 5 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Determination of prodrugs metabolizable by the liver and therapeutic use thereof
AB A method of ascertaining if a prodrug is useful for treating a disease is disclosed. The prodrug is acceptable if it is metabolized in liver cells by aldehyde oxidase to produce an active drug or metabolite. Prodrugs are shown equally effective in treating diseases as the active drug itself with many benefits and without as many associated side effects. Methods for

treating cancers with e.g. 5-iodo-2-pyrimidinone-deoxyribose are also described.
AN 1998:186491 HCAPLUS <<LOGINID::20090528>>
DN 128:239464
OREF 128:47257a,47260a
TI Determination of prodrugs metabolizable by the liver and therapeutic use thereof
IN Cheng, Yung-Chi; Chang, Chien-Neng
PA Yale University, USA
SO U.S., 24 pp., Cont.-in-part of U.S. Ser. No. 701,462, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5728684	A	19980317	US 1994-146164	19940419 <--
	ZA 9203495	A	19930331	ZA 1992-3495	19920514 <--
	WO 9220816	A1	19921126	WO 1992-US4142	19920515 <--
	W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO				
	RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, MC, ML, MR, NL, SE				
	IL 121375	A	19981206	IL 1992-121375	19920515 <--
PRAI	US 1991-701462	B2	19910515	<--	
	US 1992-829474	B2	19920203	<--	
	WO 1992-US4142	W	19920515	<--	
	IL 1992-101879	A3	19920515	<--	

OS MARPAT 128:239464
RE.CNT 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 6 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Composition for tissues to sustain viability and biological functions in surgery and storage
AB A composition composing ketone bodies and/or precursors thereof and an aqueous phosphate-buffered balanced salt solution with citrate, HPO42-, and Ca2+ in a defined concentration ratio is useful as a rich energy source for isolated tissue
and for peripheral tissues under surgery with concurrent suppression of lactic acid formation and accumulation in the cells. Methods, including a mechanism and an associated set of protocols, are provided for making the solution without causing autoclave-elicited caramelization and precipitation in the
manufacturing process. The composition may be used in ocular surgery, general surgery, and topical application, storage, and rinsing of donor tissues prior to transplantation. Thus, an irrigating solution contained Na DL-β-hydroxybutyrate 1.51, KCl 0.75, NaCl 7.71, Na2HPO4.7H2O 0.67, NaH2PO4.H2O 0.07, Na citrate-2H2O 0.59, MgCl2.6H2O 0.24, and CaCl2 0.09 mg/mL (pH 7.3-7.4). The solution was filtered, bottled, sealed under vacuum, and sterilized by autoclaving or by showers of superheated water at 121-123° for 15-20 min and immediately cooled rapidly with showers of water or in water baths in 2 stages, first at 60° and then at 4°, to prevent breakage of glass bottles. Glucose (5.5 mM) may be added to the solution without eliciting autoclave-induced caramelization.
AN 1997:527758 HCAPLUS <<LOGINID::20090528>>
DN 127:187869
OREF 127:36361a,36364a
TI Composition for tissues to sustain viability and biological functions in surgery and storage
IN Chen, Chung-ho; Chen, Sumi C.

PA USA
SO U.S., 8 pp., Cont.-in-part of U.S. 5,298,487.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5654266	A	19970805	US 1994-218109	19940328 <--
US 5298487	A	19940329	US 1992-833027	19920210 <--
PRAI US 1992-833027	A2	19920210	<--	
US 1989-346700	A3	19890503	<--	

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 7 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Methods of reducing toxicity of chemotherapeutic and antiviral agents with acylated non-methylated pyrimidine nucleosides
AB Compds., compns. and methods are disclosed for the treatment and prevention of toxicity due to chemotherapeutic agents and antiviral agents. Disclosed are acylated derivs. of non-methylated pyrimidine nucleosides. These compds. are capable of attenuating damage to the hematopoietic system in animals receiving antiviral or antineoplastic chemotherapy. Oral administration of triacetyluridine ameliorated the hematol. toxicity of 5-fluorouracil. Triacetyluridine and uridine increased the therapeutic index of 5-fluorouracil in tumor-bearing mice. Amelioration of the adverse effects of e.g. AZT is also described.
AN 1997:141015 HCAPLUS <<LOGINID::20090528>>
DN 126:139905
OREF 126:26891a
TI Methods of reducing toxicity of chemotherapeutic and antiviral agents with acylated non-methylated pyrimidine nucleosides
IN Vonborstel, Reid W.; Bamat, Michael K.
PA Pro-Neuron, Inc., USA
SO PCT Int. Appl., 142 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 13

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9640165	A1	19961219	WO 1996-US10067	19960606
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
IN 177670	A1	19970215	IN 1994-CA701	19940902 <--
US 5968914	A	19991019	US 1995-472210	19950607 <--
AU 9661114	A	19961230	AU 1996-61114	19960606
AU 724805	B2	20000928		
EP 831849	A1	19980401	EP 1996-918461	19960606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
JP 10511689	T	19981110	JP 1997-502184	19960606
AU 9952624	A	19991202	AU 1999-52624	19991001
AU 2002320811	A1	20030403	AU 2002-320811	20021223
AU 2005232288	A1	20051201	AU 2005-232288	20051110
PRAI US 1995-472210	A	19950607		

```
     US 1987-115923       B2    19871028  <--
     US 1987-115929       B2    19871028  <--
     US 1989-438493       B2    19890627  <--
     US 1990-487984       B2    19900205  <--
     US 1991-724340       B2    19910705  <--
     US 1992-903107       B2    19920625  <--
     IN 1992-CA473        A1    19920706  <--
     US 1993-61381        B2    19930514
     US 1993-176485       A2    19931230
     AU 1995-29150        A3    19950630
     WO 1996-US10067      W     19960606
     AU 1999-52624        A3    19991001
     AU 2002-320811       A3    20021223
RE.CNT  4     THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27  ANSWER 8 OF 22  HCAPLUS  COPYRIGHT 2009 ACS on STN
TI   Acylated pyrimidine nucleosides for treatment of toxicity from
     chemotherapeutic and antiviral agents
AB   The subject invention discloses compds., compns. and methods for treatment
     and prevention of toxicity due to chemotherapeutic agents and antiviral
     agents.  Disclosed are acylated derivs. of non-methylated pyrimidine
     nucleosides.  These compds. are capable of attenuating damage to the
     hematopoietic system in animals receiving antiviral or antineoplastic
     chemotherapy.  Oral administration of triacetyluridine ameliorated the
     hematol. toxicity of 5-fluorouracil.  Effects of other derivs.
     are also presented.  Synthesis of ethoxycarbonyluridine is included.
AN   1995:756200  HCAPLUS <<LOGINID::20090528>>
DN   123:160865
OREF 123:28387a
TI   Acylated pyrimidine nucleosides for treatment of toxicity from
     chemotherapeutic and antiviral agents
IN   Von Borstel, Reid Warren; Bamat, Michael Kevin
PA   Pro-Neuron, Inc., USA
SO   PCT Int. Appl., 143 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 13
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
PI   WO 9426761          A1     19941124    WO 1993-US12689        19931230
         W:  AU, CA, JP, KR
         RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
     AU 9460812           A      19941212    AU 1994-60812          19931230
     IN 177670            A1     19970215    IN 1994-CA701          19940902 <--
     AU 9952624           A      19991202    AU 1999-52624          19991001
     AU 2002320811        A1     20030403    AU 2002-320811         20021223
     AU 2005232288        A1     20051201    AU 2005-232288         20051110
PRAI US 1993-61381        A      19930514
     IN 1992-CA473        A1     19920706  <--
     WO 1993-US12689      W      19931230
     AU 1995-29150        A3     19950630
     AU 1999-52624        A3     19991001
     AU 2002-320811       A3     20021223
OS   MARPAT 123:160865
RE.CNT  6     THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27  ANSWER 9 OF 22  HCAPLUS  COPYRIGHT 2009 ACS on STN
TI   pharmaceutical compositions containing nucleic acid constituents for
```

treating amyloidosis
AB Pharmaceutical compns.(e.g. injections) for treating amyloidosis contain inosine, cytidine, GMP uridine, and thymidine at mol ratio of 4:4:4:3:1. Effectiveness was tested in exptl. animal model.
AN 1994:613002 HCAPLUS <<LOGINID::20090528>>
DN 121:213002
OREF 121:38646h,38647a
TI pharmaceutical compositions containing nucleic acid constituents for treating amyloidosis
IN Ito, Akihiro; Watanabe, Atsumitsu; Yokoyama, Hiroomi
PA Otsuka Pharma Co Ltd, Japan
SO Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 06206823	A	19940726	JP 1993-284713	19931115 <--
	JP 3306459	B2	20020724		
PRAI	JP 1992-308696	A1	19921118 <--		

L27 ANSWER 10 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Magnetic liquid compositions for imaging contrast agents
AB Magnetic liquid compns. are prepared from physiol. tolerated dispersions of stabilized superparamagnetic particles in water or aqueous salt solution and reactive stabilizer substances chemical bonded over phosphate or phosphonate or carboxylate groups to the surface of the superparamagnetic particles. The reactive stabilizer substances stabilize and chemical bond diagnostic and pharmacol. active substances. The bonded stabilizer substances protect against aggregation. Dextran phosphate was treated with magnetite to form a magnetic liquid which was further carboxymethylated and reacted with anti-human Ig. The resulting magnetic liquid composition can be used for NMR diagnosis or in vitro diagnosis (no data). Preparation of other compns. for NMR or ultrasound imaging is also described.
AN 1993:229355 HCAPLUS <<LOGINID::20090528>>
DN 118:229355
OREF 118:39559a,39562a
TI Magnetic liquid compositions for imaging contrast agents
IN Pilgrimm, Herbert
PA Silica Gel Gesellschaft mbH adsorptions-Technik, Apparatebau, Germany
SO U.S., 9 pp. Cont.-in-part of U.S. Ser. No. 173,590, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5160725	A	19921103	US 1991-638134	19910104 <--
	DE 3709851	A1	19881006	DE 1987-3709851	19870324 <--
PRAI	DE 1987-3709851	A	19870324 <--		
	US 1988-173590	B2	19880325 <--		

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 11 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Relationships between the chromatographic retention data and the effects of nucleoside derivatives in highly metastatic 3LL cells
AB The effect of 21 nucleoside derivs. on the [3H]-thymidine cellular uptake and on the incorporation into DNA of highly metastatic 3LL (Lewis lung carcinoma) cells has been measured. Hydrophobic and

hydrophilic mol. parameters (the adsorption capacity, specific adsorption surface, lipophilicity and specific hydrophobic surface area) have been determined by using TLC. Stepwise linear regression anal. and principal component anal. have been applied in order to reveal the relationships between the mol. parameters and the effect of the nucleoside derivs. on highly metastatic 3LL cells. The first principal component obtained from the measured activity data could be attributed to the change of [3H]-thymidine cellular uptake caused by the nucleoside, while the second principal component could be regarded as the measure of the effect on the DNA incorporation of [3H]-thymidine. The effect of nucleosides on the [3H]-thymidine uptake could be explained by the specific hydrophobic and adsorption surface area of the nucleoside, on the other hand the effect on the DNA incorporation could be described by the adsorption characteristics (specific hydrophilic surface area and adsorption capacity) of the derivs.

AN 1992:645002 HCAPLUS <<LOGINID::20090528>>
DN 117:245002
OREF 117:42171a,42174a
TI Relationships between the chromatographic retention data and the effects of nucleoside derivatives in highly metastatic 3LL cells
AU Pogany, G.; Cserhati, T.; Olah, J.; Valko, K.
CS Jt. Res. Organ., Hung. Acad. Sci., Budapest, H-1086, Hung.
SO Journal of Pharmaceutical and Biomedical Analysis (1992), 10(7), 495-500
CODEN: JPBADA; ISSN: 0731-7085
DT Journal
LA English

L27 ANSWER 12 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN
TI A study on the synthesis and biological activity of nucleoside chemotherapeutic agents
AB Various 5-substituted 5'-amino-5'deoxyuridine conjugates of amino acids, peptides, and penicillin G, 5'-monophosphate-fatty acid derivs. were prepared 5'-Amino-5'deoxyuridinecyclo(Phe-Asp) and 5'-iodo-5'deoxyuridine-penicillin G were the most efficient compds. against microorganisms such as Staphylococcus aureus and L5178 murine lymphoma cells. 5'-Monophosphates were more active than simple uridine derivs. suggesting that other modified nucleoside 5'-phosphates should be examined as prodrugs. The MICs of the compds. prepared are tabulated.
AN 1992:439820 HCAPLUS <<LOGINID::20090528>>
DN 117:39820
OREF 117:6839a,6842a
TI A study on the synthesis and biological activity of nucleoside chemotherapeutic agents
AU Kang, Shin Won; Kim, Kyong Hee; Shine, Jung Hee; Lee, Bong Hun; Jang, Tae Sik
CS Coll. Nat. Sci., Pusan Natl. Univ., Pusan, 609-735, S. Korea
SO Misaengmul Hakhoechi (1991), 29(6), 353-60
CODEN: MIHCAR; ISSN: 0440-2413
DT Journal
LA Korean

L27 ANSWER 13 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Synthesis, characterization and evaluation in anticancer activities of novel cis-diammineplatinum pyrimidine greens
AB Selective and efficient preparation is described of novel Pt pyrimidine green complexes by newly developed convenient 1-pot reaction. Various kinds of pyrimidine derivs. as a substrate, and of Ag salts as a counter anion were able to be used in the present reaction. As an oxidizing agent, H2O2, O2, and a series of metal oxides which possess redox potentials > 1.2 V (vs. standard hydrogen electrode in H2O) could be used, and gave reasonable yields.

All Pt greens obtained by this method showed outstanding activity against a variety of murine and human malignant cells. The 40° sample (synthesized at 40°) exerted greater activity than the 75° sample against all examined tumor cell lines, for example, resp. IC50 (μg/mL) values of 75° and 40° samples toward HeLa, L1210, U937, S-180, and Daudi cells were 2.35 and 1.10, 2.90 and 0.85, 4.86 and 1.90, 0.11 and 0.05, and 2.20 and 0.13. The 40° sample was noteworthy for its low substrate/Pt ratio, e.g., 25-38% and 60-70%, resp., for 40° and 75° samples. Relationship between the activity and mol. size of Pt greens was found, viz., relatively small mols. around Pt-decamer gave the strongest activity, but larger ones were less active. Results of HPLC anal. under various pH values and temps. are given. Studies on biol. action mechanism by a fluorescence method using a cell sorter and by uptake of 3H-thymidine suggested that the 40° sample inhibited DNA synthesis completely at an early stage of the S-phase in cell cycles. Novel thermochromic and hyperchromic behavior is reported.

AN 1991:621760 HCAPLUS <<LOGINID::20090528>>
DN 115:221760
OREF 115:37569a,37572a
TI Synthesis, characterization and evaluation in anticancer activities of novel cis-diammineplatinum pyrimidine greens
AU Shimura, Takehiko; Okada, Tomoko; Tomohiro, Takenori; Okuno, Hiroaki
CS Natl. Chem. Lab. Ind., Tsukuba, Japan
SO Kagaku Gijutsu Kenkyusho Hokoku (1991), 86(1), 11-25
CODEN: KGKHEP; ISSN: 0388-3213
DT Journal
LA Japanese

L27 ANSWER 14 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Convenient synthesis of anticancer cis-diammineplatinum pyrimidine green analogs by one-pot reaction and their evaluation of antitumor activities in vitro
AB cis-Diammineplatinum greens containing uracil, uridine, 5-fluorouracil, uridine-5'-monophosphate, and thymidine etc. have been synthesized by a 1-pot reaction. The reaction is fast, efficient and highly reliable, proceeding via in-situ generation of an aqua complex. High antitumor activity against L1210 cells has been shown with Pt pyrimidine green prepared by the 1-pot reaction. The products have accumulation effects as oligomer complexes on the active site, probably nuclear DNA. The influence of the ligands on the biol. activity is also discussed.
AN 1991:73983 HCAPLUS <<LOGINID::20090528>>
DN 114:73983
OREF 114:12413a,12416a
TI Convenient synthesis of anticancer cis-diammineplatinum pyrimidine green analogs by one-pot reaction and their evaluation of antitumor activities in vitro
AU Shimura, Takehiko; Tomohiro, Takenori; Okuno, Hiroaki
CS Natl. Chem. Lab. Ind., Tsukuba, Japan
SO Kagaku Gijutsu Kenkyusho Hokoku (1990), 85(1), 11-15
CODEN: KGKHEP; ISSN: 0388-3213
DT Journal
LA Japanese

L27 ANSWER 15 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Platinum complexes as atitumor agents
AB [(H2N)2Pt(H2O)2]2X [X = (NO3-)2 or (ClO4-)2] is treated with uridine, thymidine, uracil, thymine, 2'-deoxyuridine, uridine-5'-mopophosphate, or 5-fluorouracil in the presence of H2O2 to form a Pt complex showing antitumor activity. A solution of

cis-diaquodiamine Pt(II) sulfate (preparation given) in H2SO4 was successively treated with uridine, 0.5 N NaOH (to pH 4.3), and 1% H2O2 to give a Pt complex. The complex (10 μg/mL) inhibited the growth of L1210 tumor cells by 92.8%.

AN 1990:70002 HCAPLUS <<LOGINID::20090528>>
DN 112:70002
OREF 112:11759a,11762a
TI Platinum complexes as atitumor agents
IN Okuno, Hiroaki; Shimura, Takehiko; Tomohiro, Takenori
PA Agency of Industrial Sciences and Technology, Japan
SO Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 01125325	A	19890517	JP 1987-284567	19871111 <--
PRAI JP 1987-284567		19871111	<--	

L27 ANSWER 16 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN
TI In vitro antitumor activity of platinum pyrimidine greens obtained by one-pot synthesis on L1210 cells
AB Platinum pyrimidine complexes were prepared by the 1-pot method (described previously). The complexes were tested for biol. activity as leukemic tumor inhibitors. The inhibitory activity of these compds. is comparable to that of cisplatin with MIC values ranging from 0.85 to 3.6 μm.
AN 1989:470416 HCAPLUS <<LOGINID::20090528>>
DN 111:70416
OREF 111:11695a,11698a
TI In vitro antitumor activity of platinum pyrimidine greens obtained by one-pot synthesis on L1210 cells
AU Okuno, Hiroaki; Shimura, Takehiko; Uemura, Toshimasa; Nakanishi, Hiroshi; Tomohiro, Takenori
CS Natl. Chem. Lab. Ind., Tsukuba, 305, Japan
SO Inorganica Chimica Acta (1989), 157(2), 161-3
CODEN: ICHAA3; ISSN: 0020-1693
DT Journal
LA English

L27 ANSWER 17 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Manufacture of antitumor platinum green complexes
AB Antitumor Pt green complexes are prepared by reacting [(NH3)2Pt(H2O)2]X [X = SO42-, (NO3-)2] with uridine or thymidine in the presence of H2O2 or a photosensitizer. cis-Diaquodiammineplatinum(II) sulfate (0.3 mmol) in 3 mL water was reacted with 73.2 mg uridine at pH 4.3 in the presence of 1% H2O2 to obtain 70.6 mg Pt green complex m. >300°. The complex (70 mg/kg) was administered i.p. to mice with transplanted leukemia cell L1210. The average survival time was >60 days vs. 10 days for controls.
AN 1988:622457 HCAPLUS <<LOGINID::20090528>>
DN 109:222457
OREF 109:36633a,36636a
TI Manufacture of antitumor platinum green complexes
IN Okuno, Hiroaki; Sasaki, Takuma; Yonemitsu, Tsukasa
PA Yoshitomi Pharmaceutical Industries, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 63044591	A	19880225	JP 1986-189316	19860812 <--
PRAI	JP 1986-189316		19860812	<--	

L27 ANSWER 18 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Synthesis of antitumor platinum pyrimidine blues. Optimized reaction conditions and purification by gel filtration
AB A method is given for the efficient and highly reproducible preparation of platinum blues in a reaction of diaquo derivative of cis-Pt(NH3)2I2, and nucleosides (uridine, 2'-deoxyuridine, uridine-5'-monophosphate) via air oxidation reaction with heating. Gel filtration method was successfully used for purification of the products. Notably, uridine green species rather than the blue complexes gave remarkably high antitumor activity against L1210 cells.
AN 1988:485068 HCAPLUS <<LOGINID::20090528>>
DN 109:85068
OREF 109:14035a,14038a
TI Synthesis of antitumor platinum pyrimidine blues. Optimized reaction conditions and purification by gel filtration
AU Okuno, Yohmei; Tomohiro, Takenori; Shimura, Takehiko
CS Natl. Chem. Lab. Ind., Tsukuba, Japan
SO Kagaku Gijutsu Kenkyusho Hokoku (1988), 83(1), 27-33
CODEN: KGKHEP; ISSN: 0388-3213
DT Journal
LA Japanese

L27 ANSWER 19 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Additives and method for improving the quality and shelf life of stored blood
AB The O off-loading capacity and posttransfusion viability of whole blood and red cell concs. are improved by addition to the preservation medium of inhibitor of pyruvate kinase and 2,3-diphosphoglycerate (2,3-DPG) phosphatase along with activator of phosphofructokinase, 2,3-DPG mutase, and phosphoglycolate phosphatase to maintain intracellular 2,3-DPG and ATP levels. Among the compds. useful as pyruvate kinase inhibitors are L-amino acids, fatty acids, glycolytic intermediates, nucleosides, and nucleotides.
AN 1987:421338 HCAPLUS <<LOGINID::20090528>>
DN 107:21338
OREF 107:3581h,3582a,3583a,3584a,3585a,3586a,3587a
TI Additives and method for improving the quality and shelf life of stored blood
PA United States Dept. of Health and Human Services, USA
SO U. S. Pat. Appl., 20 pp. Avail. NTIS Order No. PAT-APPL-6-817 189.
CODEN: XAXXAV
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 817189	A0	19860718	US 1986-817189	19860108 <--
	US 4774088	A	19880927		
	WO 8704072	A1	19870716	WO 1987-US63	19870108 <--
	W: AU, DK, FI, JP, NO				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	AU 8768976	A	19870728	AU 1987-68976	19870108 <--
	EP 258290	A1	19880309	EP 1987-900956	19870108 <--
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
PRAI	US 1986-817189	A	19860108	<--	
	WO 1987-US63	A	19870108	<--	

L27 ANSWER 20 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Pharmaceuticals containing nucleic acid bases, nucleosides, and nucleotides for the treatment of liver diseases
AB A pharmaceutical contains at least 2 compds. selected from the group consisting of nucleic acid bases, nucleosides, and nucleotides for the treatment of liver diseases. Thus, di-Na 5'-AMP 2.34, di-Na 5'-CMP 2.20, di-Na 5'-GMP 2.44, di-Na 5'-UMP 1.65, thymidine 0.36, and H2O to 100% by weight/volume were mixed and dissolved, and pH was adjusted to 7.4 with HCl. The solution was sterilized by filtration, packed in injection ampuls with N, and sterilized by heating at 105° for 40 min to give injection formulations.
AN 1987:107940 HCAPLUS <<LOGINID::20090528>>
DN 106:107940
OREF 106:17591a,17594a
TI Pharmaceuticals containing nucleic acid bases, nucleosides, and nucleotides for the treatment of liver diseases
IN Ogoshi, Shohei
PA Otsuka Pharmaceutical Factory, Inc., Japan
SO Jpn. Kokai Tokkyo Koho, 15 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 61277619	A	19861208	JP 1985-121235	19850604 <--
JP 03029765	B	19910425		
PRAI JP 1985-121235		19850604 <--		

L27 ANSWER 21 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Synthesis and biological effects of acyclic pyrimidine nucleoside analogs
GI



I II

AB Twenty-two nucleoside analogs, most which are represented by I and II (R = H, Me, F, or Ac; R1 = CH2OCH2CH2O2CPh, CH2OCH2CH2N3, CH2OCH2CH2OH, etc.) were synthesized and tested for various biol. effects. At 10-4M, none of the compds. inhibited leukemia α-1210 cell growth in culture. Several compds. did inhibit the in vitro growth of Escherichia coli K-12. II (R = F, R1 = CH2OCH2CH2OH) [77474-50-1] was the most active with an IC50 (concentration for 50% inhibition) of 1.2 μM. Some of the analogs also selectively interfered with Herpes Simplex virus replication in vitro. None of the I analogs tested were either substrates or inhibitors of human liver nucleoside deaminase [9073-42-1].
AN 1981:525884 HCAPLUS <<LOGINID::20090528>>
DN 95:125884
OREF 95:20955a,20958a
TI Synthesis and biological effects of acyclic pyrimidine nucleoside analogs
AU Schroeder, Alan C.; Hughes, Robert G., Jr.; Bloch, Alexander
CS Grace Cancer Drug Cent., Roswell Park Mem. Inst., Buffalo, NY, 14263, USA

SO Journal of Medicinal Chemistry (1981), 24(9), 1078-83
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English

L27 ANSWER 22 OF 22 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Improved synthesis and in vitro antiviral activities of 5-cyanouridine and 5-cyano-2'-deoxyuridine
GI



I, R=OH
II, R=H

AB 5-Cyanouridine (I) [4425-57-4] and 5-cyano-2'-deoxyuridine (II) [26639-00-9] were prepared by treatment of the appropriate acetylated 5-bromouracil nucleoside with NaCN or KCN in Me2SO followed by deblocking. I had no significant in vitro activity against vaccinia virus, herpes simplex-1, or vesicular stomatitis virus, while II, lacking activity against herpes simplex, gave significant inhibition of vaccinia virus. Replacement of the 5-halogen substituent decreases, but does not abolish, antiviral activity.
AN 1977:415731 HCAPLUS <<LOGINID::20090528>>
DN 87:15731
OREF 87:2409a,2412a
TI Improved synthesis and in vitro antiviral activities of 5-cyanouridine and 5-cyano-2'-deoxyuridine
AU Torrence, Paul F.; Bhooshan, Bharant; Descamps, Johan; De Clercq, Erik
CS Natl. Inst. Arthritis, Metab. Dig. Dis., NIH, Bethesda, MD, USA
SO Journal of Medicinal Chemistry (1977), 20(7), 974-6
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English